131 related articles for article (PubMed ID: 17303418)
21. Synthesis and in vitro pharmacological evaluation of salvinorin A analogues modified at C(2).
Béguin C; Richards MR; Wang Y; Chen Y; Liu-Chen LY; Ma Z; Lee DY; Carlezon WA; Cohen BM
Bioorg Med Chem Lett; 2005 Jun; 15(11):2761-5. PubMed ID: 15869877
[TBL] [Abstract][Full Text] [Related]
22. Chemical syntheses of the salvinorin chemotype of KOR agonist.
Hill SJ; Brion AUCM; Shenvi RA
Nat Prod Rep; 2020 Nov; 37(11):1478-1496. PubMed ID: 32808003
[TBL] [Abstract][Full Text] [Related]
23. Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligands.
Harding WW; Tidgewell K; Byrd N; Cobb H; Dersch CM; Butelman ER; Rothman RB; Prisinzano TE
J Med Chem; 2005 Jul; 48(15):4765-71. PubMed ID: 16033256
[TBL] [Abstract][Full Text] [Related]
24. Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers.
Munro TA; Duncan KK; Xu W; Wang Y; Liu-Chen LY; Carlezon WA; Cohen BM; Béguin C
Bioorg Med Chem; 2008 Feb; 16(3):1279-86. PubMed ID: 17981041
[TBL] [Abstract][Full Text] [Related]
25. Modification of the furan ring of salvinorin A: identification of a selective partial agonist at the kappa opioid receptor.
Béguin C; Duncan KK; Munro TA; Ho DM; Xu W; Liu-Chen LY; Carlezon WA; Cohen BM
Bioorg Med Chem; 2009 Feb; 17(3):1370-80. PubMed ID: 19147366
[TBL] [Abstract][Full Text] [Related]
26. Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist.
Roth BL; Baner K; Westkaemper R; Siebert D; Rice KC; Steinberg S; Ernsberger P; Rothman RB
Proc Natl Acad Sci U S A; 2002 Sep; 99(18):11934-9. PubMed ID: 12192085
[TBL] [Abstract][Full Text] [Related]
27. Addressing Structural Flexibility at the A-Ring on Salvinorin A: Discovery of a Potent Kappa-Opioid Agonist with Enhanced Metabolic Stability.
Sherwood AM; Crowley RS; Paton KF; Biggerstaff A; Neuenswander B; Day VW; Kivell BM; Prisinzano TE
J Med Chem; 2017 May; 60(9):3866-3878. PubMed ID: 28376298
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and biological evaluation of C-2 halogenated analogs of salvinorin A.
Lee DY; Yang L; Xu W; Deng G; Guo L; Liu-Chen LY
Bioorg Med Chem Lett; 2010 Oct; 20(19):5749-52. PubMed ID: 20801035
[TBL] [Abstract][Full Text] [Related]
29. Differential helical orientations among related G protein-coupled receptors provide a novel mechanism for selectivity. Studies with salvinorin A and the kappa-opioid receptor.
Vortherms TA; Mosier PD; Westkaemper RB; Roth BL
J Biol Chem; 2007 Feb; 282(5):3146-56. PubMed ID: 17121830
[TBL] [Abstract][Full Text] [Related]
30. A unique binding epitope for salvinorin A, a non-nitrogenous kappa opioid receptor agonist.
Kane BE; Nieto MJ; McCurdy CR; Ferguson DM
FEBS J; 2006 May; 273(9):1966-74. PubMed ID: 16640560
[TBL] [Abstract][Full Text] [Related]
31. Differential signaling properties at the kappa opioid receptor of 12-epi-salvinorin A and its analogues.
Béguin C; Potuzak J; Xu W; Liu-Chen LY; Streicher JM; Groer CE; Bohn LM; Carlezon WA; Cohen BM
Bioorg Med Chem Lett; 2012 Jan; 22(2):1023-6. PubMed ID: 22204910
[TBL] [Abstract][Full Text] [Related]
32. Antinociceptive and hypothermic effects of Salvinorin A are abolished in a novel strain of kappa-opioid receptor-1 knockout mice.
Ansonoff MA; Zhang J; Czyzyk T; Rothman RB; Stewart J; Xu H; Zjwiony J; Siebert DJ; Yang F; Roth BL; Pintar JE
J Pharmacol Exp Ther; 2006 Aug; 318(2):641-8. PubMed ID: 16672569
[TBL] [Abstract][Full Text] [Related]
33. Synthesis of salvinorin A analogues as opioid receptor probes.
Tidgewell K; Harding WW; Lozama A; Cobb H; Shah K; Kannan P; Dersch CM; Parrish D; Deschamps JR; Rothman RB; Prisinzano TE
J Nat Prod; 2006 Jun; 69(6):914-8. PubMed ID: 16792410
[TBL] [Abstract][Full Text] [Related]
34. CoMFA analyses of C-2 position salvinorin A analogs at the kappa-opioid receptor provides insights into epimer selectivity.
McGovern DL; Mosier PD; Roth BL; Westkaemper RB
J Mol Graph Model; 2010 Apr; 28(7):612-25. PubMed ID: 20083418
[TBL] [Abstract][Full Text] [Related]
35. Salvinorin A: from natural product to human therapeutics.
Vortherms TA; Roth BL
Mol Interv; 2006 Oct; 6(5):257-65. PubMed ID: 17035666
[TBL] [Abstract][Full Text] [Related]
36. Isolation and chemical modification of clerodane diterpenoids from Salvia species as potential agonists at the kappa-opioid receptor.
Li Y; Husbands SM; Mahon MF; Traynor JR; Rowan MG
Chem Biodivers; 2007 Jul; 4(7):1586-93. PubMed ID: 17638340
[TBL] [Abstract][Full Text] [Related]
37. Synthetic studies of neoclerodane diterpenes from Salvia divinorum: preparation and opioid receptor activity of salvinicin analogues.
Simpson DS; Katavic PL; Lozama A; Harding WW; Parrish D; Deschamps JR; Dersch CM; Partilla JS; Rothman RB; Navarro H; Prisinzano TE
J Med Chem; 2007 Jul; 50(15):3596-603. PubMed ID: 17580847
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of the plant-derived kappa-opioid hallucinogen salvinorin A in nonhuman primates.
Schmidt MD; Schmidt MS; Butelman ER; Harding WW; Tidgewell K; Murry DJ; Kreek MJ; Prisinzano TE
Synapse; 2005 Dec; 58(3):208-10. PubMed ID: 16138318
[TBL] [Abstract][Full Text] [Related]
39. The hallucinogen derived from Salvia divinorum, salvinorin A, has kappa-opioid agonist discriminative stimulus effects in rats.
Willmore-Fordham CB; Krall DM; McCurdy CR; Kinder DH
Neuropharmacology; 2007 Sep; 53(4):481-6. PubMed ID: 17681558
[TBL] [Abstract][Full Text] [Related]
40. Autoxidation of salvinorin A under basic conditions.
Munro TA; Goetchius GW; Roth BL; Vortherms TA; Rizzacasa MA
J Org Chem; 2005 Nov; 70(24):10057-61. PubMed ID: 16292839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
